biotech · Genetic Disease · Alport Syndrome · ELOX
Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is a biotech organization headquartered in Watertown, USA. It trades on NYSE under ticker ELOX. Primary therapeutic focus areas include Genetic Disease, Alport Syndrome, Cystic Fibrosis, Genetic Dis
Watertown, USA HQ
2013 Founded
12 Employees
Public company Type
ELOX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Watertown, USA
- Founded
- 2013
- Employees
- 12
- Programs
- 7
- Drugs
- 1
- Patents
- 6
Exaluren
Phase 2 · small molecule · Alport Syndrome, X-Linked
Exaluren for Alport Syndrome, X-Linked is a Phase 2 program (small_molecule) at Eloxx Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code EL-017
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Eloxx Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Alport Syndrome, X-Linked
- Status
- active
- Trials
- 1